Sciencast Management LP Acquires Shares of 5,516 DexCom, Inc. (DXCM)

Sciencast Management LP acquired a new position in shares of DexCom, Inc. (NASDAQ:DXCM) in the 2nd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund acquired 5,516 shares of the medical device company’s stock, valued at approximately $403,000.

Several other large investors also recently bought and sold shares of DXCM. State Street Corp lifted its position in DexCom by 2.5% during the second quarter. State Street Corp now owns 1,549,843 shares of the medical device company’s stock valued at $113,374,000 after purchasing an additional 37,581 shares during the period. Janus Henderson Group PLC lifted its position in DexCom by 101,699.8% during the second quarter. Janus Henderson Group PLC now owns 6,828,731 shares of the medical device company’s stock valued at $499,522,000 after purchasing an additional 6,822,023 shares during the period. Macquarie Group Ltd. lifted its position in DexCom by 67.2% during the second quarter. Macquarie Group Ltd. now owns 242,598 shares of the medical device company’s stock valued at $17,746,000 after purchasing an additional 97,479 shares during the period. Fred Alger Management Inc. lifted its position in DexCom by 52.6% during the second quarter. Fred Alger Management Inc. now owns 2,018,116 shares of the medical device company’s stock valued at $147,625,000 after purchasing an additional 695,484 shares during the period. Finally, Goldman Sachs Group Inc. lifted its position in DexCom by 29.0% during the second quarter. Goldman Sachs Group Inc. now owns 1,808,872 shares of the medical device company’s stock valued at $132,319,000 after purchasing an additional 406,116 shares during the period.

TRADEMARK VIOLATION WARNING: “Sciencast Management LP Acquires Shares of 5,516 DexCom, Inc. (DXCM)” was reported by BBNS and is the property of of BBNS. If you are accessing this piece of content on another site, it was stolen and reposted in violation of United States & international trademark and copyright legislation. The legal version of this piece of content can be read at https://baseballnewssource.com/markets/sciencast-management-lp-acquires-shares-of-5516-dexcom-inc-dxcm/1701989.html.

In other DexCom news, EVP Steven Robert Pacelli sold 1,450 shares of DexCom stock in a transaction that occurred on Monday, September 25th. The shares were sold at an average price of $69.81, for a total transaction of $101,224.50. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, EVP Andrew K. Balo sold 3,244 shares of DexCom stock in a transaction that occurred on Thursday, August 10th. The shares were sold at an average price of $71.18, for a total transaction of $230,907.92. The disclosure for this sale can be found here. Insiders sold 29,023 shares of company stock worth $2,056,178 over the last three months. Corporate insiders own 1.70% of the company’s stock.

DXCM has been the subject of a number of research reports. Barclays PLC restated an “equal weight” rating and set a $60.00 target price (down from $76.00) on shares of DexCom in a research report on Thursday, September 28th. Citigroup Inc. downgraded shares of DexCom from an “outperform” rating to a “market perform” rating in a research report on Thursday, September 28th. BidaskClub downgraded shares of DexCom from a “buy” rating to a “hold” rating in a research report on Wednesday, July 5th. Zacks Investment Research upgraded shares of DexCom from a “sell” rating to a “hold” rating in a research report on Monday, August 14th. Finally, Leerink Swann restated a “buy” rating and set a $57.00 target price (down from $85.00) on shares of DexCom in a research report on Friday, September 29th. One research analyst has rated the stock with a sell rating, nine have issued a hold rating and fourteen have assigned a buy rating to the stock. DexCom currently has a consensus rating of “Buy” and a consensus price target of $72.19.

Shares of DexCom, Inc. (DXCM) traded down 1.1043% during trading on Monday, hitting $47.2128. 353,038 shares of the stock traded hands. DexCom, Inc. has a 52-week low of $42.62 and a 52-week high of $88.80. The company’s 50 day moving average is $67.67 and its 200 day moving average is $72.02. The firm’s market cap is $4.09 billion.

DexCom (NASDAQ:DXCM) last released its earnings results on Tuesday, August 1st. The medical device company reported ($0.16) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.23) by $0.07. DexCom had a negative net margin of 10.27% and a negative return on equity of 27.90%. The business had revenue of $170.60 million for the quarter, compared to analysts’ expectations of $166.54 million. During the same period last year, the company earned ($0.24) earnings per share. The company’s quarterly revenue was up 24.3% on a year-over-year basis. On average, equities research analysts predict that DexCom, Inc. will post ($0.80) EPS for the current year.

DexCom Profile

Dexcom, Inc (Dexcom) is a medical device company. The Company is focused on the design, development and commercialization of continuous glucose monitoring (CGM) systems for ambulatory use by people with diabetes and for use by healthcare providers. The Company’s products consist of DexCom G4 PLATINUM and DexCom G5 Mobile.

Institutional Ownership by Quarter for DexCom (NASDAQ:DXCM)

Receive News & Ratings for DexCom Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DexCom Inc. and related companies with our FREE daily email newsletter.

 


Latest News

Justin Turner Joining Postseason Legends
Justin Turner Joining Postseason Legends
PED Use Cost Alex Rodriguez Millions and His Reputation
PED Use Cost Alex Rodriguez Millions and His Reputation
Yankees to Send Masahiro Tanaka Against Astros in Game 1
Yankees to Send Masahiro Tanaka Against Astros in Game 1
Red Sox Waste Little Time in Firing John Farrell
Red Sox Waste Little Time in Firing John Farrell
Washington Nationals Sans Strasburg for Game 4 at Wrigley
Washington Nationals Sans Strasburg for Game 4 at Wrigley
Red Sox Beat Houston Sunday to Avoid Elimination
Red Sox Beat Houston Sunday to Avoid Elimination


Leave a Reply

 
© 2006-2017 BBNS.